Head to Head Comparison: Generation Alpha (OTCMKTS:GNAL) versus BioLife Solutions (NASDAQ:BLFS)

Generation Alpha (OTCMKTS:GNAL) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Profitability

This table compares Generation Alpha and BioLife Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Generation Alpha	N/A	N/A	N/A
BioLife Solutions	-3.20%	0.97%	0.87%

Institutional & Insider Ownership

93.2% of BioLife Solutions shares are held by institutional investors. 60.8% of Generation Alpha shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Generation Alpha and BioLife Solutions”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generation Alpha	N/A	N/A	N/A	N/A	N/A
BioLife Solutions	$82.25 million	14.25	-$20.18 million	($0.07)	-347.71

Generation Alpha has higher earnings, but lower revenue than BioLife Solutions.

Volatility and Risk

Generation Alpha has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Generation Alpha and BioLife Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generation Alpha	0	0	0	0	0.00
BioLife Solutions	1	1	3	0	2.40

BioLife Solutions has a consensus price target of $32.00, suggesting a potential upside of 31.47%. Given BioLife Solutions’ stronger consensus rating and higher probable upside, analysts plainly believe BioLife Solutions is more favorable than Generation Alpha.

Summary

BioLife Solutions beats Generation Alpha on 8 of the 10 factors compared between the two stocks.

About Generation Alpha

Generation Alpha, Inc. focuses on the research, design, development, and manufacturing of indoor horticulture lighting, plant nutrient products, and ancillary equipment in the United States and internationally. The company offers digital ballasts; metal halide, and mercury vapor and high-pressure sodium lamps; light emitting diode lighting products that produce less heat; digital lighting controller, a temperature monitoring control system; reflectors; and high intensity lighting accessories, as well as plant nutrients and fertilizers. It primarily serves commercial and retail cannabis growers in the medical and adult use recreational markets; distributors; and retailers. Generation Alpha, Inc. markets its products directly; and through distributors to hydroponic retailers, as well as through direct contacts, online email advertising, social media, trade magazine advertising, trade show promotions, and cross-promotional offerings, as well as ecommerce websites. The company was formerly known as Solis Tek Inc. Generation Alpha, Inc. was incorporated in 2007 and is based in Upland, California.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.